6926 Stock Overview
Research, develops, and manufactures anti-cancer related drug products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Shine-On BioMedical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$65.90 |
| 52 Week High | NT$80.00 |
| 52 Week Low | NT$60.80 |
| Beta | 0 |
| 11 Month Change | -1.20% |
| 3 Month Change | 0.30% |
| 1 Year Change | 4.60% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -14.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6926 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 1.1% | -1.0% | 0.8% |
| 1Y | 4.6% | 0.7% | 30.3% |
Return vs Industry: 6926 exceeded the TW Biotechs industry which returned 0.7% over the past year.
Return vs Market: 6926 underperformed the TW Market which returned 30.3% over the past year.
Price Volatility
| 6926 volatility | |
|---|---|
| 6926 Average Weekly Movement | 2.4% |
| Biotechs Industry Average Movement | 4.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6926 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6926's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 19 | Hongzhe Jiang | www.shineon-bio.com |
Shine-On BioMedical Co.,Ltd. research, develops, and manufactures anti-cancer related drug products. It also develops antibody anticancer drugs, such as exosome anti-cancer drugs, that includes SOB101 and SOB102; SOB201 for engineered multi-target exosomes; SOA101, a dual immune checkpoint T cell adapter antibody; and SOA201, a trispecific adapter immune cell antibody.
Shine-On BioMedical Co.,Ltd. Fundamentals Summary
| 6926 fundamental statistics | |
|---|---|
| Market cap | NT$3.28b |
| Earnings (TTM) | -NT$70.83m |
| Revenue (TTM) | NT$9.52m |
344.6x
P/S Ratio-46.3x
P/E RatioIs 6926 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6926 income statement (TTM) | |
|---|---|
| Revenue | NT$9.52m |
| Cost of Revenue | NT$2.86m |
| Gross Profit | NT$6.67m |
| Other Expenses | NT$77.50m |
| Earnings | -NT$70.83m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.42 |
| Gross Margin | 70.00% |
| Net Profit Margin | -743.71% |
| Debt/Equity Ratio | 0% |
How did 6926 perform over the long term?
See historical performance and comparison